RLMD RELMADA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1553643 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY59.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-64.7%
ROA-59.7%
ROIC (approx.)-54.7%
Asset turnover—
Leverage & solvency
Liabilities / assets5.6%
Debt / equity0.00x
Current ratio26.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $26.88M | $46.18M | $54.81M | $113.32M | $90.62M |
| SG&A expense | $32.22M | $37.72M | $48.89M | $47.93M | $35.08M |
| Operating income | -$59.10M | -$83.89M | -$103.70M | -$161.25M | -$125.70M |
| Net income | -$57.39M | -$79.98M | -$98.79M | -$157.04M | -$125.75M |
| EBITDA | — | — | — | — | -$125.70M |
| EPS (basic) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 |
| EPS (diluted) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 |
| Weighted avg. shares (diluted) | 39.48M | 30.16M | 30.10M | 29.63M | 17.55M |
| Banking | |||||
| Net interest income | — | — | $5.15M | $2.66M | $1.20M |
| Balance sheet | |||||
| Cash & equivalents | $3.50M | $3.86M | $4.09M | $5.40M | $44.44M |
| Short-term investments | $89.51M | $41.05M | $92.23M | $142.93M | $167.47M |
| Receivables | — | — | — | $512,432 | — |
| Current assets | $93.98M | $45.80M | $97.51M | $152.87M | $223.30M |
| Total assets | $94.00M | $45.82M | $97.55M | $152.91M | $223.33M |
| Current liabilities | $6.43M | $10.29M | $12.19M | $12.47M | $15.06M |
| Total liabilities | $7.49M | $10.30M | $12.19M | $12.47M | $15.06M |
| Shareholders' equity | $86.51M | $35.52M | $85.36M | $140.44M | $208.26M |
| Shares outstanding | 73.33M | 30.17M | 30.10M | 30.10M | 27.74M |
| Cash flow statement | |||||
| Operating cash flow | -$45.79M | -$51.76M | -$51.66M | -$103.80M | -$91.87M |
| Investing cash flow | -$48.14M | $51.56M | $50.45M | $19.73M | -$54.12M |
| Financing cash flow | $93.56M | -$40,341 | -$98,463 | $45.02M | $187.94M |
| Depreciation & amortization | — | — | — | — | $1,258 |
| Stock-based compensation | $13.91M | $30.18M | $43.81M | $44.19M | $40.49M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.